Ann: Appendix 4D and Interim Financial Report, page-35

Great find....I suspect you could well be onto something here OvF - and, if so, this could be very meaningful for PIQ. As you (rightly) suggest - there are a few pieces which seem to tell some sort of story

- Janssen is a leading Pharma company in the Type 2 diabetes market with one of the major SGLT2s (canagliflozin)

- Janssen had a massive win with their CREDENCE trial (which stopped early as the results were that good!)

- They operate in a very competitive sector of the market - and along with AstraZeneca who you mention in your previous post - compete against a Lilly/Boehringer product from the same SGLT2 class (Jardiance) - which had an edge in that they have a trial (EMPAREG) that shows reduction in risk of cardiovascular death in Type 2 diabetes patients

- If Janssen are successful with gaining these additional indications it'd definitely place them in a stronger position and would lead to canagliflozin being the first diabetes medicine for the treatment of people living with type 2 diabetes and CKD - which would be a big deal and attract a lot of attention

And if the collaboration with PIQ has/had anything to do with this........?!

Further to this - as your first article points out - AstraZeneca's Knowthedanger.com also seems to fit rather nicely with a certain diagnostic test able to determine future prognosis for Type 2 diabetes patients. Hello PromarkerD.

I'm new to PIQ - only been on board a few weeks after watching from the sidelines since January. Once I'd done some reading - and knowing a little about the area - I could see no reason why this shouldn't be way north of 30c - even without the licence deal in the US being sorted out.

Surely only good times ahead - as perhaps these broader developments may end up being more significant than how many kits are being sold at such an early stage of commercialisation.